Biotechnology

Avalo Therapeutics

Avalo Therapeutics released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9762 (forecast USD -1.0255)

Avalo Therapeutics released FY2025 annual earnings on March 23 (EST), actual revenue USD 59K (forecast USD 0), actual EPS USD -5.8399 (forecast USD -6.309)

Avalo Therapeutics released FY2025 Q4 earnings on March 23 (EST), actual revenue USD 59K (forecast USD 0), actual EPS USD -0.7547 (forecast USD -1.47)

Avalo Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.19 (forecast USD -1.7171)

Avalo Therapeutics released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -5.3605

Avalo Therapeutics Updates Novel IL-1β Treatment for Immune-Mediated Inflammatory Diseases

Avalo Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.9199 (forecast USD -1.4014)

Avalo Therapeutics released FY2025 Semi-Annual Earnings on August 7 (EST), with actual revenue of USD 0 and EPS of USD -3.18

Avalo Therapeutics Shareholders Elect Board Members and Approve Executive Compensation Resolution

Avalo Therapeutics signs $75 million sales agreement with TD Securities

Avalo Therapeutics Attending Two Investor Meetings

Avalo Therapeutics released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2505 (forecast USD -1.055)

Avalo Therapeutics Inc Expected To Report EPS Loss Of $1.39

Avalo Announces Progress in Anti-IL-1β Monoclonal Antibody Development

Avalo Therapeutics CEO to Speak at Citizen Life Sciences Conference

Avalo Therapeutics released FY2024 annual earnings on March 20 (EST), actual revenue 441 K USD (forecast 224.5 K USD), actual EPS -20.9087 USD (forecast -24.724 USD)

Avalo Therapeutics released FY2024 Q4 earnings on March 20 (EST), actual revenue 192 K USD (forecast 0 USD), actual EPS -3.4367 USD (forecast -1.516 USD)

Avalo Therapeutics released FY2024 9 Months Earnings on November 7, 2024 (EST) with actual revenue of USD 249K and EPS of USD -147.8312

Avalo Therapeutics released FY2024 Q3 earnings on November 7 (EST), actual revenue $249,000 (forecast $0), actual EPS -2.834 (forecast -1.19)

Avalo Therapeutics Inc Regains Compliance with Nasdaq Listing Rules

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AVTX

IBBQ

SBIO

HC Wainwright analysts have raised their Q2 2026 EPS estimate for Avalo Therapeutics from ($1.04) to ($0.59) per share, maintaining a 'Buy' rating with a $35.00 price target. The consensus for the full-year earnings is ($3.00) per share. Avalo's stock has a consensus rating of 'Moderate Buy' and a target price of $48.13. Recent insider sales and institutional investments have also been noted.

Market Beat

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Piper Sandler Cos

Mizuho Financial

Citizens Financial

Mizuho Financial Group, Inc.

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst

ARKG

Citizens Jmp has lowered its price target for Avalo Therapeutics (NASDAQ:AVTX) from $62.00 to $55.00, maintaining a "market outperform" rating. This new target suggests a potential upside of 182.85% from the stock's previous close. Other analysts have also provided mixed ratings, with a consensus rating of "Moderate Buy" and a price target of $48.13. Avalo's stock is currently trading down 2.0% at $19.45, with a market cap of $570.32 million. Recent insider transactions indicate significant share sales by executives.

Ark Genomic Revolution ETF

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00

LABU

Avalo Therapeutics reported a narrower Q1 loss of 98 cents per share, beating estimates of $1.13. Positive results from the Phase 2 LOTUS trial for abdakibart signal a transformative period for the company. Analysts maintain Buy ratings but adjust price targets: HC Wainwright lowers from $40 to $35, Mizuho raises from $39 to $45, and Wedbush lowers from $40 to $34. Avalo shares closed at $19.85.

benzinga_article

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results

Avalo Therapeutics, Inc. (AVTX) has highlighted new risk factors in its Form 10-Q, urging investors to consider these when evaluating the company's outlook. An external reviewer emphasizes that existing risks could significantly impact Avalo's operations and financial health. The average stock price target for AVTX is $46.89, indicating a potential upside of 136.22%.

Tip Ranks

Proshares Ultra Nasdaq Biotech

Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty

TMED

Avalo Therapeutics, Inc. has seen its 12-month stock price target cut to $47.82, suggesting a potential upside of 144%. The average price target from 10 analysts has increased from $48.1 to $48.7, with estimates ranging from $35 to $62 per share. The consensus rating remains a "Buy" with 12 analysts recommending buys and none holding or selling. This information is based on the latest analyst forecasts and does not constitute investment advice.

TradingView

T. Rowe Price Health Care ETF

iShares Global Healthcare

VG Health

Blackrock Future Health ETF

iShares US Pharma

Health Care Select Sector SPDR

Factset Research

Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside

Avalo Therapeutics, Inc. reported its first-quarter 2026 results, showing a revenue of $19.7M and a net loss of $19.63M, reflecting a year-over-year decline in both metrics. The company achieved positive Phase 2 results for its drug abdakibart in treating hidradenitis suppurativa, supporting plans for Phase 3 trials. R&D and G&A expenses increased to prepare for pivotal trials, and the company completed a $405M follow-on offering to fund operations through 2029.

Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary

Earnings Watch

Avalo Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Avalo Therapeutics (NASDAQ:AVTX) experienced a significant increase in trading volume after Citizens JMP raised its price target from $52 to $62, resulting in an 85% rise in volume to approximately 1.7 million shares. The stock closed at $22.55, up from $21.81. Analysts have generally rated the stock positively, with several upgrades following positive trial results and a $375 million public offering. However, concerns about dilution and insider selling may affect short-term performance.

Avalo Therapeutics (NASDAQ:AVTX) Sees Large Volume Increase Following Analyst Upgrade

BLMN

FLEX

COMP

VECO

VCYT

SMCI

Entravision Comm(EVC) rose 93.22%, with a trading turnover 289.7 Million USD, and a year-to-date rose 166.9%. Bloomin Brands(BLMN) rose 40.97%, with a trading turnover 90.2 Million USD, and a year-to-date rose 31.6%. Flex(FLEX) rose 39.69%, with a trading turnover 2.4 Billion USD, and a year-to-date rose 123%.

- The Nasdaq Composite Index rose by 2.02%, with a year-to-date increase of 11.2%.  
- Entravision Communications (EVC) surged by 93.22%, achieving a total trade volume of $290 million and a year-to-date rise of 166.9%.  
- Bloomin Brands (BLMN) increased by 40.97% with $90.2 million in trading volume, while Flex International (FLEX) climbed 39.69% with $2.41 billion in trading volume and a 123% year-to-date increase.

Avalo Therapeutics(AVTX.US)